Navigation Links
Neogen Reports First Quarter Revenue and Net Income Increases
Date:9/27/2011

LANSING, Mich., Sept. 27, 2011 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its revenues for the first quarter of FY 2012, which ended Aug. 31, increased 6.5% to $45,697,000, from the previous year's first quarter revenues of $42,923,000. The current year's revenue increase is almost entirely comprised of products available in the prior year's first quarter.

First quarter net income increased 3.1% from the prior year to $6,004,000, or $0.25 per share. This compares to net income of $5,824,000 in the first quarter of FY 2011, also $0.25 per share. The first quarter revenues and net income represent quarterly records for the 29-year-old company.

"In the first quarter we continued our remarkable quarter-to-quarter success in consistent growth in sales and profits, while at the same time implementing our plan to ensure long-term growth," said James Herbert, Neogen's chief executive officer and chairman. "I'm very proud of our management team and employee group, who have kept our strong quarter-to-quarter growth going for more than 20 years."

The quarter marked the 74th consecutive profitable quarter from operations for the company, and was the 78th of the past 83 quarters when Neogen reported revenue increases as compared with the previous year — including the last 26 consecutive quarters.

"We are pleased to report yet another solid quarter, in spite of a difficult comparison with our previous fiscal year's first quarter. Last year at this time we reported a first quarter revenue increase of 33% that was bolstered by a significant spike in sales of two test kits primarily resulting from unusual weather conditions," said Lon Bohannon, Neogen's president and chief operating officer. "During the first quarter we were also able to move forward with some infrastructure improvements intended to accelerate future growth, including com
'/>"/>

SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin
2. Neogen Reports 30% Increase in Net Income
3. Neogen Corporation Announces Year-End Results Conference Call
4. Neogen Acquires VeroMara from GlycoMar Ltd.
5. William T. Boehm Joins Neogens Board of Directors
6. Neogen Reports 27% Increase in Quarterly Net Income
7. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
8. Neogen Names Quinlan as CFO
9. Neogen Reports 33% Increase in Net Income
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ore. , July 22, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today announced that ... before the open of U.S. financial markets on July ... Semler will host a conference call at 11 a.m. ...
(Date:7/22/2014)... 2014 Holomic is expanding its ... of its fluorescent immunoassay reader, the HRDR-300, at ... in Chicago, July 28-31, 2014. Available in both ... HRDR-300 is a highly sensitive, low-cost fluorescent reader ... lateral flow immunoassays with high sensitivity and accuracy. ...
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the constantly ... greatest health care system in the world is too ... trying to serve the public. Unfortunately, Bush has also ... enormous system that none of them can first describe ... of Open Letters ( http://is.gd/wdU2CM ) provides a critique ...
(Date:7/21/2014)... College of Arts and Sciences has received a ... nanoparticles. , Mathew M. Maye, associate professor of ... from the National Science Foundation (NSF). The award ... nanostructures, the results of which may impact gas ... , Maye,s approach is novel, in that ...
Breaking Biology Technology:Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:7/22/2014)... team from the National Institute of Standards and ... demonstrated a dramatically improved technique for analyzing biological ... "signatures." The new NIST technique is an advanced ... but one that delivers signals that are 10,000 ... and 100 times stronger than obtained from comparable ...
(Date:7/22/2014)... reputation as disease causing agents, some viruses can ... to shape the world we live in today, ... Academy of Microbiology. , "Viruses participate in essential ... the planet, from contributing to biogeochemical cycles, shaping ... states Marilyn Roossinck of Pennsylvania State University, a ...
(Date:7/22/2014)... promise for treating damaged organs and tissues, but with ... their effectiveness. New methods are being developed and tested ... after transplantation, as described in a Review article in ... Mary Ann Liebert, Inc., publishers. The article is available ... website . , In the article ,Preconditioning ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Researchers speaking in the first plenary session of the ... (IAS 2011) have today offered insights into current and ... developments over the past two years are beginning ... policy. The presentations reflect the breadth of expertise ...
... trailing a long length of rope behind you is not ... to manoeuvre, and can get tangled up or stuck on ... apart during cell division. The chromosomes are pulled by their ... Just like climbers carry their rope coiled up, cells make ...
... PHILADELPHIA The use of trastuzumab, chemotherapy and ... improved survival from the time central nervous system metastases ... researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now ... chemotherapy, even if cancer spreads to the brain." ...
Cached Biology News:Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 2Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 3Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 4Keeping it together 2Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients 2